Rabies antibody product: Phase I data

In a double-blind, placebo-controlled, U.S. Phase I trial in 57 healthy volunteers, CRXL's rabies monoclonal antibody cocktail was well tolerated and elicited neutralizing antibodies. Volunteers also ...